Form 4: Lyell Immunopharma Director William Rieflin Acquires 130,000 Stock Options
SEC Form 4 Filing
Director William Rieflin acquired 130,000 stock options in Lyell Immunopharma, Inc. on June 14, 2024, according to a Form 4 filing with the SEC.
Summary
- William Rieflin, a director of Lyell Immunopharma, Inc., reported the acquisition of 130,000 stock options on June 14, 2024.
- The options have an exercise price of $2.36.
- The options vest on the earlier of the next annual meeting of stockholders following June 14, 2024, or the first anniversary of June 14, 2024, contingent upon continuous service.
- The options expire on June 13, 2034.
- A Power of Attorney was executed on June 14, 2024, granting Matthew Lang, Charles Newton, Hector Casab, Anitha Anne, and Allison Peth the authority to act on behalf of William Rieflin for Section 16 filings.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard SEC filing indicating a director's acquisition of stock options, which can be interpreted as a positive sign but doesn't provide enough information for a strong positive or negative assessment.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry. It reflects a director's investment in the company, which can be seen as a sign of confidence.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of earliest transaction (acquisition of stock options) and execution of Power of Attorney. |
| 06/14/2024 | Date the option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 14, 2024 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 14, 2024, subject to the Reporting Person providing continuous service through such date. |
| 06/13/2034 | Expiration date of the acquired stock options. |
| 06/17/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.